Summary: In this 24-week double-blind feasibility trial of 12 adults with post-surgical hypothyroidism, levothyroxine (LT4) monotherapy did not normalize free T4 or total T3, whereas LT4-liothyronine (LT3) combination therapy kept these within range. Between-group differences in body weight, cholesterol, TSH, and quality of life were all non-significant, so no efficacy conclusion can be drawn from this exploratory sample.
PICO Summary
| Element | Detail |
|---|---|
| Population | 12 adults (10 women, 2 men; mean age 51 plus or minus 13.8 years) undergoing total thyroidectomy and requiring hormone replacement; single academic medical center, USA. Double-blind, placebo-controlled, 24-week feasibility RCT (NCT05682482). |
| Intervention | LT4 plus LT3 5 mcg twice daily; LT4 titrated at 6 and 12 weeks to baseline TSH plus or minus 0.5 mcIU/mL (n = 5). |
| Comparison | LT4 plus placebo twice daily, same LT4 titration protocol (n = 7). |
| Outcome | No significant TSH difference between arms. Within the LT4/placebo arm, free T4 rose (+0.26 plus or minus 0.15, p<0.005) and total T3 fell (-18 plus or minus 9.6 ng/dL, p<0.003); these shifts were absent with LT4/LT3. Body weight (LT4/placebo +1.7 plus or minus 3.8 kg vs LT4/LT3 -0.6 plus or minus 1.9 kg), total cholesterol (+43.1 plus or minus 72.8 vs -28.8 plus or minus 49.0 mg/dL) and LDL (+32.0 plus or minus 64.4 vs -19.0 plus or minus 28.3 mg/dL) all changed in opposite directions but were non-significant in both arms. ThyPRO-39 quality of life showed non-significant improvement in both groups; no 95% CIs, ARR, or NNT were reported. |
Expert Commentary
This is a feasibility study, and it should be read as a proof-of-concept signal rather than evidence of clinical benefit. The verdict is that LT4 monotherapy left free T4 elevated and total T3 reduced relative to the pre-operative set point, and adding LT3 prevented that biochemical drift; the metabolic outcomes that matter to patients, namely weight and cholesterol, moved in a favorable direction with combination therapy but did not reach statistical significance. The dominant limitation is the sample: with only twelve participants split seven to five, the trial is underpowered for any clinical endpoint, and the weight and lipid differences are entirely compatible with chance. The design is otherwise reassuring, being double-blind and placebo-controlled with a pre-registered protocol, and no manufacturer sponsorship or implausibly large effect is evident. Can I use this with my patients? Not yet. The findings do not justify routinely adding liothyronine after thyroidectomy, though they do support the biological rationale and help identify a thyroidectomy cohort, who lack residual endogenous T3, as a sensible population for a properly powered trial. Adequately sized, longer-term studies with patient-reported and cardiovascular endpoints are needed before combination therapy can be recommended outside research settings.
References
Phan GQ, Yavuz S, Stamatouli AM, Madan R, Chen S, Grover AC, et al. A feasibility double-blind trial of levothyroxine vs. levothyroxine-liothyronine in postsurgical hypothyroidism. Front Endocrinol (Lausanne). 2025;16:1522753. doi:10.3389/fendo.2025.1522753
